First Trust Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.8M Buy
133,810
+39,658
+42% +$4.12M 0.01% 1127
2026
Q2
$9.18M Buy
+94,152
New +$8.22M 0.01% 1248
2022
Q3
– Sell
-3,455
Closed -$66K – 2506
2022
Q2
$66K Sell
3,455
-93
-3% -$2.3K ﹤0.01% 2468
2022
Q1
$165K Sell
3,548
-206
-5% -$11.3K ﹤0.01% 2485
2021
Q4
$266K Buy
3,754
+475
+14% +$47.7K ﹤0.01% 2409
2021
Q3
$382K Buy
+3,279
New +$382K ﹤0.01% 2336

Other funds holding DNTH

First Trust Advisors's DNTH Position: Q3 2026 in Review

First Trust Advisors increased its Dianthus Therapeutics (DNTH) stake by 42% in Q3 2026, buying an estimated $4.12M and bringing the position to 133,810 shares worth $11.8M. The position accounts for 0.01% of the portfolio, ranked #1127.

First Trust Advisors first reported a position in DNTH in Q3 2021 and has held it in 6 quarters since. 275 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • First Trust Advisors held 133,810 shares of Dianthus Therapeutics worth $11.8M as of Q3 2026.
  • First Trust Advisors bought 39,658 Dianthus Therapeutics shares in Q3 2026, an estimated $4.12M.
  • Dianthus Therapeutics made up 0.01% of First Trust Advisors's portfolio in Q3 2026, its #1127 holding.
  • First Trust Advisors first reported a position in Dianthus Therapeutics in Q3 2021 and has held it in 6 quarters since.
  • 275 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on First Trust Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.